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ABSTRACT 
Orthodontic tooth movement involves activation of osteoblasts and osteoclasts in 
response to mechanical forces. Extracellular nucleotides, released in response to mechanical 
stimuli, signal through P2 receptors in osteoblasts. P2X7 receptors are ATP-gated cation 
channels implicated in mechanotransduction in bone. Corticosteroids such as dexamethasone 
exhibit anti-inflammatory effects and their chronic use has been linked to serious side-effects 
such as osteoporosis. We investigated gene expression following P2X7 receptor activation 
with benzoylbenzoyl-ATP (P2X7 receptor agonist) in osteoblast precursor cells in the 
presence or absence of dexamethasone. We hypothesized that dexamethasone inhibits the 
ability of ATP to stimulate the expression of anabolic (bone forming) genes in osteoblasts. 
We showed that benzoylbenzoyl-ATP stimulation of Ptgs2 and Dmp1 expression is indeed 
inhibited by dexamethasone. Thus, intracellular events following activation of P2X7 may be 
important in regulating osteoblast differentiation, maturation and eventual bone formation 
during orthodontic tooth movement and dexamethasone may adversely affect these 
processes.  
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INTRODUCTION 
1 Bone Physiology and Orthodontic Tooth Movement 
Orthodontic tooth movement (OTM) is made possible by the complex interaction 
between applied force and biologic response of the bone tissues. Understanding of the 
intricate mechanisms by which mechanical stimuli are transformed into biologic 
responses will aid in developing protocols for optimizing orthodontic tooth movement. 
Tooth movement is accomplished by a coordinated activity of cells residing in the 
periodontal ligament (PDL), circulating blood, and the surrounding bone (Figure 1). The 
pressure-tension theory, the classic theory of OTM, states that chemical signals act as the 
stimulus for cellular differentiation, resulting in bone remodeling and ultimately tooth 
movement (Krishnan and Davidovitch, 2006; Schwarz, 1932). Sustained pressure causes 
the tooth to shift within the PDL space, compressing the ligament on the pressure side 
and stretching it on the tension side. This leads to fluid expression, as well as decreased 
perfusion and hypoxia on the compression side while blood flow is maintained or 
increased on the tension side (Khouw and Goldhaber, 1970).  
The combined effect of mechanical stimulus and alterations in the blood flow and oxygen 
levels create changes in the chemical environment resulting in the release of cytokines, 
prostaglandins, growth factors and other chemical messengers within a few hours. 
Animal experiments have revealed that within four hours of sustained force application 
there is an increase in the nucleotide cyclic adenosine monophosphate (cAMP) 
(Davidovitch et al., 1972). cAMP acts as a cytosolic second messenger, regulating 
cellular functions such as differentiation of the local cells in the PDL with the capacity to 
differentiate to form osteoclasts (bone removing cells) and osteoblasts (bone forming 
cells) (Roberts, 1989). Studies have also shown that important mediators of cellular 
response such as prostaglandin, interleukin-1 beta (IL-1) and nitric oxide (NO) levels 
increase within the PDL (Krishnan and Davidovitch, 2006). Furthermore, Kang and 
colleagues have shown that focal adhesion kinase (FAK) may act as the mechanoreceptor 
in PDL cells and mediate PGE2 release (Kang et al., 2010).    
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Figure 1. Biological basis of orthodontic tooth movement as explained by the 
pressure-tension theory 
Upon orthodontic force application, areas of pressure and tension are created as indicated 
in the schematic. OTM can be explained by two-fold. 1) The PDL is compressed in the 
pressure side and stretched in the tension side. The mechanical effects on cells of the 
PDL cause them to release of cytokines, prostaglandins, and other chemical messengers. 
2) The change in the PDL space alters the blood flow - it is decreased on compression 
side and maintained or increased on the tension side. This can create changes in the 
oxygen levels which then stimulates the release of other chemical messengers. These 
factors then directly or indirectly stimulate cellular differentiation and activity. Cascade 
of signaling events eventually lead to activation of osteoclasts on the pressure side 
leading to bone resorption while osteoblasts form on the tension side to lay down newly 
formed bone. (Figure adapted from www.askanorthodontist.com) 
 
 
3 
 
Once differentiated, osteoclasts must remove bone on the compressed side of the PDL 
while osteoblasts form new bone on the tension side for tooth movement to occur (Figure 
1). The cellular activity in the bone surrounding the teeth during orthodontic tooth 
movement is similar to the cellular activity involved in physiological bone remodeling. 
1.1 Bone Structure and Function 
Bone is a highly specialized and complex connective tissue that constitutes the skeleton. 
It is lightweight yet strong and serves multiple functions. Bone supports and protects vital 
organs, provides mechanical stability for body posture, serves as a site for muscle 
attachment to support locomotion and is involved in the regulation of calcium and 
phosphate mineral homeostasis (Baron, 2003). In addition, it serves as the primary site of 
hematopoiesis as it supplies a source of hematopoietic and mesenchymal stem cells 
(Clarke, 2008).  
Bone is composed of a mineralized extracellular matrix containing both organic and 
inorganic components. The organic portion of bone is primarily composed of collagen 
type I and make up approximately 35% of bone mass. Type 1 collagen is an elastic 
protein that provides bone with its tensile strength and flexibility and hence fracture 
resistance (Baron, 2003). Non-collagenous proteins, such as bone sialoprotein (BSP), 
osteocalcin (OCN), and osteopontin (OPN), are also present and are thought to regulate 
the mineralization process (Clarke, 2008). A variety of cells including osteoblasts and 
osteoclasts also make up a small portion of the organic phase. The inorganic components 
of bone composes 65% of bone mass and consist of hydroxyapatite crystals 
[Ca10(PO4)6(OH)2] (Hadjidakis and Androulakis, 2006). These crystals pack tightly 
around collagen in the extracellular matrix, contributing to the hardness and resistance to 
compressive loading giving bone its rigidity (Clarke, 2008)   
The skeleton is composed of two types of bones: an axial skeleton which includes the 
vertebrae, pelvis, and other flat bones such as the skull and sternum, and an appendicular 
skeleton which includes all of the long bones (Baron, 2003). Long bones are most bones 
in the limbs and include the humerus, radius, ulna, femur, tibia and fibula. They are 
divided into three parts: the epiphysis, metaphysis and diaphysis (Clarke, 2008). The 
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epiphysis is the portion of the long bone at either end and develops from a center of 
ossification. It is separated from the rest of the bone by a layer of growth cartilage known 
as the “physis”. The metaphysis is the zone between the physis and the central portion of 
the long bone shaft known as the diaphysis (Clarke, 2008).  
Anatomically, bone is organized into an external layer of cortical (dense or compact) 
bone, an internal network of trabecular (spongy or cancellous) bone and bone marrow 
that resides within the trabecular spaces (Clarke, 2008). The epiphyses and metaphyses 
are comprised of a trabecular network, while the diaphysis is made of dense compact 
bone.  
Bone is in contact with the soft tissues along two surfaces: an external surface (the 
periosteal surface) and an internal surface (the endosteal surface). These surfaces are 
lined with osteogenic cells along the periosteum and the endosteum, respectively (Baron, 
2003). 
Bone is formed by a process referred to as ossification. During the fetal stage, this occurs 
by two processes: intramembranous ossification and endochondral ossification (Baron, 
2003). Intramembranous ossification involves the formation of bone from connective 
tissues such as the mesenchyme whereas in endochondral ossification, bone is formed 
from cartilage (Clarke, 2008). Intramembranous ossification mainly occurs in the flat 
bones of the skull and also occurs in the mandible, maxilla and clavicle. Endochondral 
ossification occurs in the long bones and other bones in the body (Baron, 2003; Clarke, 
2008). 
The alveolar processes of the maxilla and the mandible provide the housing for the 
dentition. The maxillae consist of two maxilla bones forming the upper jaw and palate of 
the mouth. It develops entirely by intramembranous ossification and is thought to be 
ossified from a center of mesenchymal condensation in the maxillary process that appear 
during the sixth week of prenatal development (Proffit, 2012). Postnatal growth of the 
maxilla occurs by apposition of bone at sutures that connect maxilla to cranium and 
cranial base as well as by surface remodeling. The body of the mandible develops from 
the condensation of mesenchyme just lateral to Meckel’s cartilage and proceeds entirely 
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by intramembranous bone formation (Proffit, 2012). The condylar cartilage initially 
develops as a secondary cartilage and fuses with the developing mandibular ramus in the 
early fetal stages. Both endochondral and intramembranous ossification are important in 
the growth of the mandible. The surface of the mandibular condyle is covered by 
cartilage where endochondral changes occur. The rest of the mandible are formed and 
grows by intramembranous ossification (Proffit, 2012). 
1.2 Bone Cells and Their Functions  
Three major cell-types are found within bone: the bone-resorbing osteoclast, the bone-
forming osteoblast and the mechanosensitive osteocyte (terminally differentiated 
osteoblast) (Baron, 2003). Skeletal development and bone remodelling depend on the 
communication among the bone cells and the coordinated activity of osteoblasts and 
osteoclasts referred to as “coupling” (Clarke, 2008). 
1.2.1 Osteoblasts 
Cells of the osteoblast lineage develop from mesenchymal progenitor cells residing in the 
bone marrow and the periosteum that also give rise to other cell-types including 
chondrocytes, adipocytes, and fibroblasts (Harada and Rodan, 2003; Minguell et al., 
2001; Robling et al., 2006). The major function of mature osteoblasts is to synthesize and 
secrete osteoid, the organic phase of the bone matrix, and regulate its mineralization 
(Clarke, 2008). Osteoblast differentiation is characterized by lineage commitment, 
proliferation, maturation and matrix mineralization. It is regulated by a number of 
systemic hormones and local factors such as insulin-like growth factors and bone 
morphogenetic proteins (BMPs). Osteoblast activity is regulated in an autocrine/paracrine 
manner by these factors whose receptors can be found on osteoblasts (Baron, 2003). 
In the last few decades, extensive work has gone into studying osteoblastogenesis from 
mesenchymal progenitors to a mature bone-forming cell, and the involvement of a 
number of key transcription factors and transcriptional co-activators have been 
discovered. These factors function at specific times during osteoblast differentiation and 
their expression defines the different stages of the osteoblast lineage. 
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First, the chondrocyte master transcription factor sex-determining region Y (SRY)-box 9 
(SOX9) is up-regulated in the mesenchymal progenitors that give rise to either 
chondrocytes or osteoblasts (Akiyama et al., 2005). The osteoblast master transcription 
factor runt-related transcription factor 2 (RUNX2) is then expressed and push the 
proliferating precursor cells to the osteoblast lineage resulting in the formation of 
osteochondroprogenitors. Subsequent downregulation of SOX9 gives rise to RUNX2-
positive osteoprogenitors. (Bendall and Abate-Shen, 2000; Ducy et al., 1997; Robling et 
al., 2006). At this stage, RUNX2 further mediates expression of osteoblast-specific genes, 
including collagen type I (COL1) and alkaline phosphatase (ALP), and the upregulation 
of Osterix (OSX), a second osteoblast master transcription factor (Nishio et al., 2006). In 
turn, OSX regulates expression of COL1 and bone sialoprotein (BSP) and, together with 
RUNX2, promotes formation of the preosteoblast also known as immature osteoblast. 
Further differentiation of the preosteoblast into a mature osteoblast requires the 
expression of RUNX2, OSX and the canonical Wnt signaling pathway (β-catenin, 
TCG/LEF1) (Ducy et al., 1997; Glass et al., 2005; Nakashima et al., 2002). The 
transcription factor ATF-4 also plays an important role in the later stages of osteoblast 
differentiation. In summary, ATF-4, OSX, and RUNX2 are all required for osteoblast 
differentiation. In addition, the canonical Wnt transcriptional coactivator β-catenin is also 
necessary at all stages of osteoblast differentiation.  
Aside from the transcription factors, osteoblasts also exhibit differential gene expression 
specific for the developmental stage. During preosteoblast proliferation, genes required 
for the activation of proliferation (e.g. c-Fos, c-Jun, and c-Myc) and cell cycle 
progression (e.g., histones and cyclines) are expressed along with the expression of genes 
encoding growth factors (fibroblast growth factor [FGF], insulin-like growth factor-1 
[IGF-1], transforming growth factor [TGF]), BMPs, cell adhesion proteins (e.g., 
fibronectin) and COL1 (Feldman, 2013).  
Following the initial proliferation, a second stage of gene expression is associated with 
the maturation and organization of the bone extracellular matrix (ECM). During this 
stage, collagen synthesis continues and undergoes cross-link maturation. Genes 
responsible for rendering the extracellular matrix competent for mineralization (e.g. ALP) 
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are also up-regulated (Feldman, 2013). ALP hydrolyzes ester bonds in organic phosphate 
compounds under alkaline conditions and is crucial in bone calcification (Anderson, 
1989). As such, high ALP activity correlates to extracellular matrix formation in 
osteoblasts before initiation of mineralization (Gerstenfeld et al., 1987). 
Signals for the third stage involve down-regulation of genes involved in proliferation as 
well as gene expression related to the accumulation of HA in the ECM. Genes encoding 
non-collagenous proteins with mineral-binding properties (osteopontin (OPN), 
osteocalcin (OCN) and bone sialoprotein (BSP)) exhibit maximal expression during 
matrix mineralization (Feldman, 2013). BSP is a glycosylated and sulfated 
phosphoprotein found almost exclusively in mineralized connective tissues. During bone 
formation, BSP becomes the nucleus for HA formation (Hunter and Goldberg, 1993). 
OPN is a highly phosphorylated protein which is a prominent component of the 
mineralized matrix (Oldberg et al., 1986). OCN is the most abundant non-collagenous 
protein expressed preferentially by osteoblasts and can bine to calcium ions (Boivin et al., 
1990; Wolf, 1996). Active mature osteoblasts then secrete type I collagen and other 
matrix proteins towards the bone formation surface (Clarke, 2008).  
As a row of active osteoblasts secretes unmineralized matrix (osteoid) and advances away 
from the bone surface, a small number of cells fall behind and become incorporated into 
the matrix (Clarke, 2008). These osteoblasts begin to generate cytoplasmic processes and 
become an immature osteocyte. As the matrix matures and mineralizes, the osteocyte 
begins to mature and express a new set of genes, including those that encode dentin 
matrix protein-1 (Dmp1), matrix extracellular phosphoglycoprotein (Mepe), and 
sclerostin (Sost) (Feng et al., 2003; Nampei et al., 2004).  
Finally, in mature mineralized cultures, collagenases are elevated, apoptotic activity 
occurs, and compensatory proliferative activity is evident. This stage appears to serve as 
editing/remodeling function for modifications in the ECM (Feldman, 2013). At the 
completion of bone formation, 50 - 70% of osteoblasts undergo apoptosis, with the 
balance becoming osteocytes or bone-lining cells (Clarke, 2008). 
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1.2.2 Osteoclasts 
In contrast to osteoblasts, osteoclasts form by the fusion of mononucleated precursors of 
the monocyte/macrophage lineage derived from hematopoietic origins (Boyle et al., 
2003; Teitelbaum and Ross, 2003). The main function of osteoclasts is bone resorption. 
Receptor activator of NF-kappa B ligand (RANKL) is critical for osteoclast formation 
while macrophage-colony stimulating factor (M-CSF) is required for the proliferation, 
survival, and differentiation of osteoclast precursors, as well as osteoclast survival and 
cytoskeletal rearrangement required for bone resorption. RANKL and M-CSF are 
produced in both membrane-bound and soluble forms mainly by marrow stromal cells 
and osteoblasts (Boyce and Xing, 2008; Boyle et al., 2003; Ross, 2006). Osteoprotegerin 
(OPG), also produced by stromal cells and osteoblasts, is a decoy protein that occupies 
RANKL binding sites with high affinity to inhibit its action at the RANK receptor (Boyce 
and Xing, 2008; Boyle et al., 2003). OPG action on osteoclast precursors and mature 
osteoclasts prevents new osteoclast generation and induces apoptosis in existing 
osteoclasts. Hence, the ratio of RANKL and OPG ultimately determines 
osteoclastogenesis (i.e. higher RANKL:OPG ratio leads to more activation of the RANK 
receptor and osteoclast maturation) (Blair and Athanasou, 2004).  
Osteoclasts are characterized by the presence of multiple nuclei, abundant mitochondria 
an extensive Golgi apparatus, and numerous vesicles filled with lysosomal enzymes and 
vacuoles containing acid phosphatase. The most prominent feature of an actively 
resorbing osteoclast is its ruffled border with deep plasma membrane folds in the region 
in contact with the bone matrix (Baron, 2003). Active osteoclasts create an acidic 
microenvironment within this region via secretion of hydrogen ions to dissolve bone 
minerals, while secreting various protease and other hydrolases such as cathepsin K to 
degrade the organic matrix which is mostly composed of type I collagen (Novack and 
Teitelbaum, 2008). 
1.2.3 Osteocytes 
Osteocytes are terminally differentiated osteoblasts that support bone structure and 
metabolism (Clarke, 2008). Their function is poorly understood but have been implicated 
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in mechanosensation, transducing stress signals from bending or stretching of bone into 
biologic activity of other bone cells (Rubin and Lanyon, 1987). Flow of canalicular fluid 
in response to external forces induces a variety of responses within osteocytes 
(Bonewald, 1999). Rapid fluxes of bone calcium across filipodial gap junctions are 
believed to stimulate transmission of information between osteoblasts on the bone surface 
and osteocytes within the bone (Plotkin, 2011).  
1.3 Bone Remodeling  
The structural integrity and functionality of bone are maintained throughout life by 
remodeling, a process that involves the coordinated resorption of old or damaged bone 
and its replacement with newly mineralized bone matrix. Bone remodeling also plays an 
important role in maintaining plasma calcium homeostasis (Clarke, 2008). A coordinated 
balance between osteoclastic bone resorption and osteoblastic bone formation is essential 
for a healthy and functional skeleton. Under physiological conditions, resorption and 
formation are tightly coupled, and any imbalance to this process results in a variety of 
skeletal disorders such as osteoporosis and inflammatory diseases including rheumatoid 
arthritis and periodontitis (Novack and Teitelbaum, 2008). Bone remodeling is also 
particularly relevant in orthodontic tooth movement as it is a prerequisite for tooth 
movement to occur. 
The bone remodeling cycle consists of four consecutive phases: activation of osteoclast 
precursors; resorption, during which osteoclasts digest old bone (2 – 4 week); reversal, 
when mononuclear cells appear on the bone surface; and formation, when osteoblasts lay 
down new bone until the resorbed bone is replaced (4 – 6 months) (Baron, 2003; Clarke, 
2008). (Figure 2) The regulation of bone remodeling is both systemic and local. The 
major systemic regulators include parathyroid hormone (PTH), calcitriol, calcitonin and 
other hormones such as growth hormone, glucocorticoids, and sex hormones. Factors 
such as insulin-like growth factors (IGFs), prostaglandins (PGs), tumor growth factor- 
(TGF-), bone morphogenetic proteins (BMPs), and cytokines are involved as well (Blair 
and Athanasou, 2004; Boyle et al., 2003). Furthermore, through the 
RANK/RANKL/OPG system, the processes of bone resorption and formation are tightly 
coupled allowing bone formation to follow each cycle of bone resorption.  
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Bone homeostasis is maintained by differential gene expression in bone cells mediated by 
a specific stimulus mentioned above. Each of these stimuli activates specific intracellular 
signalling pathways that have been implicated in bone remodeling. Exogenous signals are 
recognized by cellular receptors found on the cell membrane. Cell membrane receptors 
are then activated and transfer the information across the cell’s cytoplasm to the nucleus 
through a cascade of intracellular signaling events that involve a complex set of 
transduction mechanisms. Intracellular receptors bind the stimulus and then translocate 
that effector to the nucleus where the receptor agonist complex binds to a specific DNA 
promotor sequence of a gene resulting in the expression of a specific gene. 
Signaling pathways implicated in bone formation thus far are: adenosine 3’,5’-cyclic 
monophosphate (cAMP)/protein kinase A (PKA) and MAPK; Wnt/-catenin; 
Ca2+/NFAT; and PI3K/AKT signaling pathway (Greenblatt et al., 2013; Marie, 2002; 
Soltanoff et al., 2009). Only the signaling pathways pertinent to this thesis are discussed 
in the following section.  
Ca2+/NFAT signaling pathway involves stimulation of specific receptors that result in 
elevations of cytosolic Ca2+. This in turn activates calcineurin, an enzyme that 
dephosphorylates NFATc1-4 transcription factors leading to their nuclear translocation 
and transcriptional activation (Hogan et al., 2003; Macian, 2005; Rao et al., 1997). 
Ca2+/NFAT pathway has been shown to regulate osteoclastogenesis (Boyle et al., 2003; 
Novack and Teitelbaum, 2008; Teitelbaum and Ross, 2003) and play important roles in 
regulation of osteoblast proliferation, differentiation and function (Koga et al., 2005; Sun 
et al., 2005). 
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Figure 2. Bone Remodeling by osteoblasts and osteoclasts 
Bone remodeling is a process that involves the removal of old bone by osteoclasts and its 
replacement by osteoblasts. It occurs in four phases: activation, resorption, reversal and 
formation. In response to localized damage to the bone matrix or the actions of systemic 
hormones, factors are released from osteoblast lineage cells resulting in recruitment of 
monocyte/macrophage precursors to the bone surface. Differentiation of these precursors 
leads to formation of a mature osteoclast characterized by its attachment to the bone 
surface and formation of a specialized apical membrane structure termed the ruffled 
border. Transport of protons and secretion of hydrolytic enzymes across the ruffled-
border membrane causes dissolution of bone mineral and degradation of the organic 
matrix. The activation and resorption phases take ~3 weeks to complete, and end with 
death of the osteoclast by apoptosis. During reversal, factors released either from the 
bone matrix or directly by the osteoclast lead to recruitment and proliferation of 
mesenchymal progenitor cells at the site of resorbed bone which then differentiate to 
form osteoblasts. Over the next 3 - 4 months, osteoblasts form bone through secretion of 
an organic matrix composed primarily of collagen type 1 (COL1), termed osteoid, and 
regulate its subsequent mineralization. During this process, a number of osteoblasts 
become embedded within the matrix and terminally differentiate into osteocytes, the most 
abundant cell-type in bone. (Figure courtesy of Dr. M.W. Grol; PhD Thesis (2013)) 
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The Wnt/-catenin-dependent canonical signaling pathway also plays an important role 
in bone formation and remodeling (Robinson et al., 2006). It up-regulates the expression 
of genes which induce the differentiation and maturation of osteoblast precursor cells and 
induces an increase in the OPG:RANKL ratio, thus inhibiting osteoclastogenesis (Issack 
et al., 2008; Kobayashi and Takahashi, 2008; Kubota et al., 2009). 
2 Mechanotransduction in Bone and Orthodontic Tooth Movement 
2.1 Mechanotransduction 
Mechanotransduction refers to the process by which external mechanical stimuli is 
translated into biological response. The skeleton remodels in response to physical forces 
(Wolff’s Law) and this process is thought to depend on the detection of mechanical 
deformation or fluid-shear by osteocytes (Wolff, 1892). Mechanical loading is considered 
a particularly potent stimulus in eliciting bone remodeling and ultimately leads to a 
localized increase in the rate of bone remodeling (Robling et al., 2006). While the exact 
mechanism underlying mechanotransduction is poorly understood, mechanical load-
induced strains in the cells and in their extracellular matrix and stresses of fluid flow can 
mediate changes in gene expression (Robling et al., 2006). When bone is mechanically 
loaded, bending causes fluid movement in the canalicular network, which leads to shear 
stress on integrin and actin molecules on the cell surface of osteocytes (Robling et al., 
2006). Fluid shear stimulates Adenosine 5-triphosphate (ATP) release which then binds 
to cell-surface purinergic receptors to trigger a cascade of downstream signaling 
pathways that ultimately culminates in initiation of osteoclastogenesis and differentiation 
of osteogenic cells thus promoting bone formation and remodeling (Robling et al., 2006).  
Skeletal mechanotransduction makes orthodontic tooth movement possible. Applied 
orthodontic forces are transmitted to local cells in the periodontal ligament and alveolar 
bone, stimulating the cells to release secondary signaling molecules that induce pro-
inflammatory, angiogenic, and osteogenic properties as described in the previous 
sections. These, in turn, trigger the process of remodeling of the periodontal ligament and 
adjacent alveolar bone via gene expression. There is now conclusive evidence that 
mechanotransduction is mediated by nucleotide release and subsequent purinergic 
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receptor signaling in bone (Dixon and Sims, 2000; Robling et al., 2006) and this may 
have important implications for OTM. 
2.2 Link between Mechanical Stimulation, Nucleotide Signaling and Bone Formation 
ATP is present in the cytoplasm of mammalian cells at concentrations of 2 - 5 mM 
(Orriss et al., 2010). ATP has long been recognized as an intracellular energy source, but 
it also plays an important regulatory role in a variety of biological processes. ATP is 
released from cells constitutively and in response to mechanical stimulation, osmotic 
swelling, shear stress and inflammation (Bodin and Burnstock, 2001; Burnstock, 2007), 
and is thought to be a key mediator in skeletal cell responses to mechanical stimuli 
(Dixon and Sims, 2000; Lenertz et al., 2011; Panupinthu et al., 2008; Robling et al., 
2006; Robling and Turner, 2009). Smaller amounts are released during neurotransmission 
and paracrine signalling, while massive amounts are released in response to trauma and 
cell lysis (Burnstock, 2007). ATP released from stimulated cells trigger intracellular Ca2+ 
increases within 1 minute after mechanical loading (Genetos et al., 2005). ATP release 
from osteoblasts in vivo has been reported to range from 1-100 M (Orriss et al., 2009). 
Following its release, ATP can act as an extracellular signaling molecule via interactions 
with specific purinergic receptors to mediate a wide variety of processes. These processes 
include neurotransmission (Edwards et al., 1992), inflammation (Perregaux and Gabel, 
1994), stimulation of secretion (Chan et al., 1995; Chander et al., 1995), regulation of cell 
proliferation (Weihs et al., 2014), induction of apoptosis (Chow et al., 1997), and bone 
remodeling (Jones et al., 1997; Morrison et al., 1998). Subsequently, other second 
messengers such as PGE2 (Rawlinson et al., 1991; Reich et al., 1997) and nitric oxide 
(NO) (Rawlinson et al., 1996) are released from the mechanically stimulated cells and 
lead to the induction of MAP-kinase signaling (ERK1/2) and c-Fos expression (Bowler et 
al., 1999; Jessop et al., 2002; Lean et al., 1996). 
It is now widely accepted that nucleotides released by cells in response to mechanical 
stimuli act in an autocrine or paracrine fashion to regulate osteoblast and osteoclast 
function by binding to cell surface purinergic receptors (Buckley et al., 2003; Genetos et 
al., 2005; Orriss et al., 2009; Romanello et al., 2005). As such, ATP and purinergic 
receptors are important modulators of both osteoblast and osteoclast activity and hence 
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the bone remodeling process. The nucleotide induced signaling may help explain the 
physiological responses of skeletal tissues to mechanical stimuli.   
3 Purinergic Receptors 
Extracellular ATP acts through binding to specific receptors on the cell surface called 
purinergic receptors. Purinergic receptors are a family of cell surface receptors activated 
by purines and pyrimidines (ATP, ADP, UTP, UDP, UDP-glucose) and are classified into 
P1, P2X and P2Y subclasses (Burnstock, 1976; Fredholm et al., 1997). P1 receptors are a 
family of G protein-coupled receptors activated by extracellular adenosine. P2 receptors 
are activated by nucleotides and are subdivided into two classes: P2X (ATP-gated cation 
channels) and P2Y (G protein-coupled receptors) (Burnstock, 2007).  
3.1 P2 Receptors 
P2 receptors play important roles in regulating cellular physiology and pathology and are 
implicated in bone remodeling. In mammals, eight P2Y receptor subtypes are known 
(P2Y1, 2, 4, 6, 11-14) whereas seven members of the P2X family (P2X1-7) are known to 
exist (Burnstock, 2007). They are present in a variety of cell types, including osteoblasts 
and osteoclasts (Burnstock, 2004; Dixon and Sims, 2000; Lenertz et al., 2011; Orriss et 
al., 2010). In bone, ATP released by mechanical stress (Romanello et al., 2005) binds to 
P2 receptors on cells of the osteoblast and osteoclast lineages, resulting in remodeling 
(Buckley et al., 2003; Dixon and Sims, 2000; Lenertz et al., 2011)  
The P2X family of receptors are ligand-gated ion channels permeable to Na+, K+, and 
Ca2+ (Khakh and North, 2006). P2X receptor channels are formed by three subunits, 
assembled either as homo- or heterotrimers. Binding of ATP to a P2X receptor causes a 
conformational change in the shape of the receptor, which results in pore formation and 
membrane depolarization. Each P2X subunit possesses intracellular carboxyl and amino 
termini containing consensus binding motifs, transmembrane domains that line the ion 
pore; and a large extracellular loop that participates in ATP binding (Burnstock, 2007).  
3.2 P2X7 Receptors 
Among the P2X subclass of receptors, the P2X7 receptor is unique in its molecular 
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structure, expression and function (Burnstock, 2007; Jacobson et al., 2002; North, 2002). 
It is a 595 amino acid polypeptide with two transmembrane domains and a long 
intracellular C-terminus compared to the other P2X receptors (Denlinger et al., 2001; 
Surprenant et al., 1996). P2X7 receptors exhibit additional distinctive features from the 
other P2X receptor family members. These include the requirement of relatively high 
concentrations of ATP for activation (in the range of 1 mM as compared to < 100 M 
required for other P2X receptors) and 10-30 times more potent activation by 2’,3’-O-(4-
benzoylbenzoyl)-ATP (BzATP) than by ATP itself (Bianchi et al., 1999; Surprenant et 
al., 1996). Acute activation of P2X7 receptors via short exposure to ATP rapidly opens a 
reversible non-selective cation channel within milliseconds allowing the influx of Ca2+, 
Na+, and K+, while sustained activation leads to the formation of large pores that allow 
permeation of hydrophilic molecules – up to 900 Da - within seconds (North, 2002). In 
humans, the P2X7 gene is highly polymorphic and genetic differences within P2X7 affect 
receptor pore formation and channel function.  
P2X7 receptors are highly expressed on immune cells including glial cells, macrophages 
and other antigen-presenting cells (Surprenant et al., 1996). The presence of P2X7 
receptors on immune cells implicates them in immune function and inflammatory 
responses. Moreover, P2X7 may affect neuronal cells by regulating the processing and 
release of interleukin-1β (IL-1β), a key mediator in neurodegeneration, chronic 
inflammation and chronic pain. Specifically, changes in the intracellular concentration of 
potassium induce the release of IL-1β, whose active form is a potent pro-inflammatory 
cytokine (Colomar et al., 2003). Active IL-1β induces a cascade of events including the 
production of superoxide products (Parvathenani et al., 2003) and tumor necrosis factor α 
(TNF-α) (Woolf et al., 1997), both of which have roles in generation or maintenance of 
pain. The accumulation of intracellular calcium also leads to the release of chemical 
mediators, such as PGE2 and IL-1α and β, all of which have been implicated in 
inflammation and bone biology (Brough et al., 2003; Gudipaty et al., 2003; Li et al., 
2005).  
Prolonged activation of P2X7 leads to the formation of large pores, which is followed by 
cytoskeletal rearrangement such as membrane blebbing, leading eventually to cell death 
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in immune cells. Considering the overall distribution of P2X7 receptors on pro-
inflammatory cells and the functional properties of P2X7 receptors, it is not surprising 
that many studies have been conducted to determine the role of P2X7 in inflammation. 
Labasi et al. examined the response of the P2X7 knockout (KO) mice in a monoclonal 
antibody-induced arthritis model and showed that arthritis severity was significantly 
attenuated in P2X7 KO mice (Labasi et al., 2002). Moreover, another study by Chessell 
et al. showed that P2X7-deficient animals did not develop symptoms of pain following a 
standard induction of inflammatory status (Chessell et al., 2005). Recent findings such as 
these implicate P2X7 in mediating inflammatory pain. As such, a search for selective 
antagonists has been pursued by pharmaceutical companies. 
3.3 P2X7 in Bone Cells 
Expression of P2X7 receptors in osteoclasts and osteoblast in rodent and human cells has 
been consistently reported in a number of publications (Buckley et al., 2003; Burnstock 
and Verkhratsky, 2009; Gartland et al., 2001; Grol et al., 2009; Nakamura et al., 2000; 
Orriss et al., 2006; Volonte et al., 2006). However, only a subpopulation of bone derived 
and calvarial osteoblasts demonstrate a positive nucleotide response (Gartland et al., 
2001; Ke et al., 2003; Panupinthu et al., 2008), indicating a possible heterogeneous 
expression of P2X7 in the cells (Agrawal and Gartland, 2015; Grol et al., 2009).  
Growing evidence implicates P2X7 in the induction of osteogenic differentiation of 
human MSCs (Sun et al., 2013). Sun and colleagues show that ATP release following 
shockwave treatment led to downstream p38 MAPK activation and c-Fos, and c-Jun 
mRNA transcription mediated by P2X7 (Sun et al., 2013). Moreover, shockwave-induced 
differentiation of MSCs was significantly reduced by the targeted inhibition of P2X7 
adding further evidence of a P2X7 mediated effect (Sun et al., 2013). In another study, 
P2X7 was shown to enhance osteogenic differentiation and mineralization in bone 
marrow-derived MSC cultures from postmenopausal women (Noronha-Matos et al., 
2014). In post-menopausal women, an impaired osteogenic commitment in ageing MSCs 
is seen as compared to those from younger females. However, osteogenic differentiation  
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Figure 3: Consequence of ATP stimulation of P2X7 receptors in osteoblasts vs. 
osteoclasts  
This general schematic indicates the potential roles for P2X7 receptor signaling in bone. 
ATP and other nucleotides are released from cells of the osteoblast lineage in response to 
mechanical stimuli. ATP released into the extracellular environment can act in an 
autocrine and/or paracrine manner to signal through multiple cell-surface P2 receptors 
subtypes on osteoblasts and osteoclasts, regulating bone remodeling. P2X7 activation in 
osteoblasts have been shown to stimulate bone formation, whereas its activation in 
osteoclasts induces apoptosis resulting in reduction in bone resorption. Thus, the P2X7 
receptor may be part of a sophisticated mechanism modulating bone remodeling upon 
mechanical loading. (Image reprinted with permission from Purinergic Signalling, Grol 
et al., 2009; Appendix B) 
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and mineralization in postmenopausal MSC cultures were restored by P2X7 activation 
with BzATP (Noronha-Matos et al., 2014). These findings suggest that P2X7 may indeed 
promote the differentiation of MSCs into mature osteoblasts, resulting in enhanced bone 
formation.   
Signaling pathways activated by P2X7 receptors have been extensively studied in several 
cell types (Budagian et al., 2003; Burnstock, 2002; Donnelly-Roberts et al., 2004; Ferrari 
et al., 1999; Gendron et al., 2003; Humphreys et al., 2000). Activation of P2X7 receptors 
couples to production of the potent lipid mediator lysophosphatidic acid (LPA) in cells of 
the osteoblast lineage, resulting in dynamic membrane blebbing and enhanced 
osteogenesis (Panupinthu et al., 2007; Panupinthu et al., 2008). Activation of 
phospholipase A2 (PLA2) by P2X7 receptors can also lead to synthesis of eicosanoids 
such as prostaglandins via cyclooxygenase pathways. PLA2 releases arachidonic acid, the 
main component of phospholipids of the cell membrane, which can then be metabolized 
by 2 pathways - the cyclooxygenase pathway involving cyclooxygenase 1 (COX1) and 
cyclooxygenase 2 (COX2) and the lipoxygenase pathway. COX1 is constitutively found 
in almost all tissues and is tissue protective. COX2 is activated during inflammatory 
processes occurring due to cell injury to produce prostaglandins in large amounts. The 
end products of P2X7 activation, LPA and PGE2, have been implicated in 
mechanotransduction induced by P2X7. However, much of the signalling pathways and 
downstream events following P2X7 receptor activation in osteoblasts remain to be 
elucidated. 
3.4 P2X7 Expression and Polymorphisms in Humans  
The P2X7 gene is located on chromosome 12q24.31, spanning 53 kb with 13 exons 
(Buell et al., 1998). It is highly polymorphic with 40 identified single nucleotide 
polymorphisms that, in some cases, lead to loss or gain of function mutations (Husted et 
al., 2013; Wesselius et al., 2011; Wesselius et al., 2013b). 
It is hypothesized that variability in the expression of the P2X7 receptor is an important 
factor in the individual variation to applied orthodontic loads and may provide the key to 
understanding why some individuals are more prone to external apical root resorption 
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(Hartsfield, 2009; Viecilli et al., 2009b). Furthermore, loss-of-function polymorphisms in 
the P2X7 receptor are associated with lower bone mineral density (Wesselius et al., 
2013a), accelerated bone loss (Gartland et al., 2012) and increased osteoporosis risk 
(Grol et al., 2009; Husted et al., 2013; Jorgensen et al., 2012; Ohlendorff et al., 2007; 
Wesselius et al., 2013a). More specifically, Ohlendorff et al. reported that 10-year 
fracture incidence in postmenopausal women is significantly associated with the 
Glu496Ala and Ile568Asn polymorphisms of the P2X7receptor (Ohlendorff et al., 2007). 
The authors also show that the Glu496Ala polymorphism results in decreased 
susceptibility of osteoclasts to ATP-induced apoptotic death. Impaired osteoclast 
apoptosis may enhance overall bone resorption, consistent with the increase in facture 
incidence and with the skeletal phenotype of the P2X7 KO mouse described by Ke and 
colleagues (Ke et al., 2003). 
3.5 P2X7 and Its Role in Mechanotransduction 
The role of the P2X7 receptor in osteoblast function has been highly debated. Early 
reports suggested that P2X7 receptor activation caused enhanced osteoblast apoptosis 
(Gartland et al., 2001). On the other hand, more recent studies suggest that P2X7 
stimulation leads to increased membrane blebbing and bone formation, possibly mediated 
via increased production of lysophosphatidic acid (LPA) and prostaglandin E2 (PGE2) 
(Li et al., 2005; Panupinthu et al., 2007; Panupinthu et al., 2008). Activation of P2X7 
receptors by exogenous nucleotides in vitro has been shown to couple to production of 
LPA and PGE2, resulting in increased osteoblast differentiation and matrix mineralization 
(Li et al., 2005). The P2X7 receptor is also thought to mediate the ERK1/2 activation 
caused by fluid shear stress in osteoblast-like cells (Liu et al., 2008).  
Ke et al. analyzed the long bone skeletal phenotype of P2X7 knockout (KO) mice. In 
femurs, it was observed that knockout animals had significant reduction in periosteal 
circumference (bone diameter), but not in length (Ke et al., 2003). This indicates that 
P2X7 has a role in regulating radial bone growth (periosteal bone formation) and 
expansion of the bone marrow cavity, but not longitudinal bone growth. In addition, 
femurs displayed significant reduction in cortical bone content and total bone content. In 
tibias, trabecular bone displayed an increased number of osteoclasts and a significant 
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reduction in mass (Ke et al., 2003). This result strongly suggests that the reduction in 
trabecular bone mass was due to increased osteoclast-mediated resorption. In addition, 
periosteal bone formation was significantly decreased (Ke et al., 2003).  
Interestingly, the skeletal phenotype of a second P2X7 KO mouse model has been 
described by Gartland and coworkers with contrasting findings (Gartland et al., 2003). 
These mice showed no overt skeletal phenotype with the exception of thicker cortical 
bones than wild-type controls. This discrepancy may be due to the presence of a splice 
variant that escaped deletion in these P2X7 KO mice, resulting in tissue-specific 
expression of functional P2X7 receptors in these KO mice models (Nicke et al., 2009).  
Based on findings from the P2X7 KO mouse described by Ke and colleagues (which 
have no functional P2X7 receptors), P2X7 receptors appear to be required for normal 
skeletal growth and anabolic responses to mechanical stimulation as the balance between 
bone formation and resorption seems to be affected in the knockout animals. Thus, the 
absence of P2X7 receptor could result in a disturbance in the coordination of bone cell 
activities (Li et al., 2005; Panupinthu et al., 2008).  
3.6 Controversy Regarding P2X7 Function in Osteoblasts 
Underlying mechanism of P2X7 activation in osteogenesis is still unclear. There are 
contradicting evidence for the effects of P2X7 activation on osteoblast differentiation and 
matrix mineralization in vitro. Previous studies in our lab have shown that P2X7 
activation in rat calvaria-derived osteoblasts lead to osteoblast differentiation and bone 
formation (Panupinthu et al., 2008). However, a recent study by Orriss et al. reported 
inhibition of bone formation with P2X7 activation in osteoblasts derived from the same 
source (Orriss et al., 2012; Orriss et al., 2013). Difference in the culture methodologies 
between the two groups may explain the discrepancy. Upon investigation into the 
experimental set-up, we noted a difference in the culture media used to cultivate the cells. 
Orriss et al. added dexamethasone (10 M) in the growth media in an effort to encourage 
osteoblast differentiation and bone formation. We believe that dexamethasone may be the 
reason behind the conflicting findings between the two groups.  
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4 Steroids and Bone 
Corticosteroids are a class of chemicals that includes the steroid hormones produced in 
the adrenal cortex as well as the synthetic analogues of these hormones. They are 
involved in a wide range of physiological processes such as stress response, immune and 
inflammatory response, carbohydrate and protein metabolism, regulation of blood 
electrolyte levels and behavior (Loeb, 1976; Swartz and Dluhy, 1978).  
Glucocorticoids such as cortisol control carbohydrate, fat and protein metabolism, and 
are anti-inflammatory by preventing phospholipid release, decreasing eosinophil action 
and a number of other mechanisms.  Mineralocorticoids such as aldosterone control 
electrolyte and water levels, mainly by promoting sodium retention in the kidney. 
Dexamethasone and its derivatives are almost pure glucocorticoids while prednisone and 
its derivatives have some mineralocorticoid action in addition to the glucocorticoid effect.  
Dexamethasone is a synthetic corticosteroid with anti-inflammatory and immune-
modulatory properties against many conditions. Synthetic glucocorticoids are therefore 
used to treat diseases caused by an overactive immune system, such as rheumatic 
arthritis, a number of skin diseases, severe allergies, asthma, and even in certain types of 
cancers among others. They are also used as immunosuppressive medications after organ 
transplantation. Their anti-inflammatory effect is based on the indirect blocking of PLA2 
and the suppression of the synthesis of both COX1 and COX2 leading to inhibition of 
prostaglandin and leukotriene synthesis (Coutinho and Chapman, 2011). Their 
immunosuppressive action is due to the inhibition of interleukins and IFN- (Coutinho 
and Chapman, 2011). In dentistry, a low dose of dexamethasone is orally administered to 
patients before and after wisdom teeth extraction for reduction of post-operative swelling. 
(Sortino and Cicciu, 2011). 
Glucocorticoids exert their effects by binding to the glucocorticoid receptor (GR) in the 
cytosol. When the glucocorticoids bind to GR, the primary mechanism of action is via 
regulation of gene transcription. The activated GR complex up-regulates expression of 
anti-inflammatory proteins in the nucleus and down-regulates the expression of pro-
inflammatory proteins by preventing translocation of pro-inflammatory transcription 
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factors from the cytosol into the nucleus (Rhen and Cidlowski, 2005). The GR is 
expressed in almost every cell in several forms. It induces many different effects in 
different part of the body, which renders glucocorticoid its pleiotropic effects including 
many harmful side effects. 
Long-term use of corticosteroids has been associated with a number of side effects such 
as thrush, bone loss, cataracts, easy bruising or muscle weakness (Buchman, 2001). A 
serious adverse effect worth noting is glucocorticoid-induced osteoporosis. 
Glucocorticoids are involved in bone physiology but the exact mechanism is unclear. It 
has been shown that osteoblasts and osteoclasts express glucocorticoid receptors and this 
expression is affected by pro-inflammatory factors such as IL-6 and IL-11 (Angeli et al., 
2002). Glucocorticoids increase bone resorption by stimulating osteoclastogenesis by 
shifting the RANKL:OPG ratio (Hofbauer et al., 1999) and by stimulating collagenase 3 
post-transcriptionally (Knauper et al., 1996). It has also been demonstrated that 
glucocorticoids inhibit new bone formation by directly inhibiting intestinal calcium 
absorption and indirectly affecting the level of sex hormones. Glucocorticoids have been 
shown to reduce estrogen levels and increase parathyroid hormone levels in the blood 
leading to decreased bone formation (Canalis and Delany, 2002). In addition, the 
expressions of paracrine factors such as insulin-like growth factor (IGF-I) and growth 
hormone are also influenced (Heck et al., 1997). The changes in hormone levels and 
bioactive molecules closely associated with bone metabolism seem to result in a 
disturbance in bone homeostasis.  Glucocorticoid induced inhibition of new bone 
formation and stimulation of bone resorption leads to bone dysplasia such as osteoporosis 
(Olney, 2009).   
A few studies have looked at the effects of glucocorticoids and OTM. However, the 
difference in the experimental design such as the animal model, dosages, induction 
periods, and the relative anti-inflammatory activity of the glucocorticoids seem to create 
discrepancy in the findings (Bartzela et al., 2009). In rabbits, cortisone administration 
was shown to result in a significant increase in the rate of OTM. The relapse rate was also 
faster in the treatment group as compared to the control (Ashcraft et al., 1992). In rats, 
prednisolone was shown to have no significant effect on the rate of tooth movement 
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while a similar study done with methylprednisolone show increase in the rate of tooth 
movement (Ong et al., 2000). Kalia and colleagues looked at the response of rat alveolar 
bone upon acute and chronic methylprednisolone administration with or without 
orthodontic forces (Kalia et al., 2004). Acute corticosteroid treatment led to a reduction in 
bone turnover but the rate of tooth movement was unaffected. In the chronic group, the 
degree of resorption was doubled which led to an increased rate of tooth movement. The 
authors conclude that with chronic glucocorticoid use, the rate of active tooth movement 
is greater, however this results in unstable final tooth position (Kalia et al., 2004). They 
suggest that it is possible to treat patients on corticosteroid therapy with some 
adjustments. For patients with short-term administration of the drug, it may be best to 
postpone orthodontic treatment until the chronic phase is over and the patient is off the 
medication. If the patient is already undergoing orthodontics, appliance adjustments 
should be kept at minimal and the appointments should be scheduled with longer 
intervals as bone turnover will likely be delayed and OTM could take longer in the acute 
phase of glucocorticoid therapy. For patients undergoing long-term drug therapy, the rate 
of tooth movement will be increased and the orthodontic appliance can be controlled as 
usual or more frequently. It may also be necessary to decrease the amount of force used. 
Furthermore, once the patient is in the retention phase of orthodontic treatment, a more 
rigorous retention protocol may be recommended (Kalia et al., 2004). 
5 Rationale, Hypotheses and Objectives of the Research 
Given the importance of purinergic signaling in osteoblast differentiation and function, 
the objective of this project was to investigate the signal transduction pathways that 
function downstream of P2X7 in cells of the osteoblast lineage. As described above, there 
is a controversy regarding the consequences of P2X7 receptor activation in osteoblasts. In 
this study, we investigated the downstream events that follow BzATP activation of P2X7, 
specifically in gene expression. Considering the important role of P2X7 plays in skeletal 
mechanotransduction, we hypothesized that P2X7 activation induces the expression of 
anabolic genes involved in bone formation in osteoblasts. Furthermore, we hypothesized 
that this anabolic effect of P2X7 on gene expression is inhibited by glucocorticoids. In 
the present study, we assessed effects of the glucocorticoid dexamethasone (Figure 4). 
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Target genes of interest are those implicated in osteogenesis such as transcription factors 
responsible for osteoblast proliferation and differentiation as well as genes that encode 
bone matrix proteins. 
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Figure 4. Controversy regarding the consequences of P2X7 receptor activation in 
osteoblasts 
This general schematic summarizes the current controversy surrounding the exact role 
P2X7 plays in osteoblast function and eventual bone formation. Left panel indicates the 
findings from past lab members of Dr. Dixon’s laboratory. Observations from Dr. 
Dixon’s lab have consistently shown stimulation of bone formation with ATP-induced 
P2X7 activation in osteoblasts (Panupinthu et al., 2008; Grol et al., 2009). Right panel 
shows the observations of a U.K. group led by Dr. Arnett. In contrast to the findings from 
our lab, they have shown that ATP activation of P2X7 in osteoblasts leads to inhibition of 
bone formation. Differences observed may be attributed to the differences in the culture 
condition used by the two groups. 
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MATERIALS AND METHODS 
1 Materials and Solutions 
α-Minimum essential medium (α-MEM), heat-inactivated fetal bovine serum (FBS), 
antibiotic solution (10,000 U/ml penicillin, 10,000 mg/ml streptomycin, and 25 mg/ ml 
amphotericin B), trypsin solution, Dulbecco’s phosphate buffered saline (DPBS) were 
obtained from GIBCO (Life Technologies Inc., Burlington, ON, Canada). TRIzol reagent 
and UltraPure distilled water (DNase/RNase-free) were obtained from Invitrogen (Life 
Technologies). RNeasy Mini Kit was from QIAGEN (Toronto, ON, Canada). qScript 
XLT One-Step RTqPCR Toughmix ROX was purchased from Quanta. Primers and 
probes for Ptgs2 (COX2, Mm00478374_m1), Dmp1 (Mm01208363_m1), c-Fos 
(Mm00487425_m1), Mepe (Mm_02525159_s1), Col1a1 (Mm00801666_g1), Bglap 
(osteoclacin; Mm03413826_mH), c-Myc (Mm00487804_m1), Mmp9 
(Mm00442991_m1), Alpl (alkaline phosphatase; Mm01187113_g1) and 18S rRNA were 
obtained from Applied Biosystems (Life Technologies).  2’-3’-O-(4-benzoylbenzoyl) 
adenosine 5’-triphosphate triethylammonium salt (BzATP) was obtained from Sigma-
Aldrich (St. Louis, MO, USA). 
2 Cell Culture 
The MC3T3-E1 osteoblast precursor cell line (subclone 4) was obtained from the 
American Type Culture Collection (Rockville, MD, USA). MC3T3-E1 cells were 
subcultured twice weekly and maintained in α-MEM, supplemented with 10% FBS and 
1% antibiotic antimycotic solution (culture medium) at 37C and 5% CO2.  
3 RNA Isolation 
Total RNA was extracted using TRIZOL® reagent (Invitrogen, Paisley, UK) and RNeasy 
according to the manufacturer's instructions. Total RNA was quantified 
spectrophotometrically by measuring absorbance at 260 nM. RNA was diluted to 25ng/l 
in RNase free water, aliquoted and stored at −80 °C until amplification by Real-Time RT-
PCR.  
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4 Real-Time RT-PCR Analyses 
MC3T3-E1 cells (mouse calvarial preosteoblasts) were plated at a density of 1.5x104 
cells/cm2 on Falcon 6-well plates in culture medium. After 2 days, cells were placed in 
serum-free medium and incubated overnight. Select wells were pre-treated with 
dexamethasone (100 nM) or vehicle (100% ethanol) overnight (Figure 5). On the day of 
the experiment, cells were incubated with BzATP (300 M) or vehicle (divalent cation 
free buffer, DCFB) for the indicated times and total RNA was isolated as mentioned 
above. Real-time PCR was performed using the ABI Prism 7900 HT Sequence Detector 
(PerkinElmer) with 15 l final reaction volumes containing 25 ng RNA sample, qScript 
XLT One-Step RTqPCR Toughmix, and one of Ptgs2, c-Fos, Mepe, Dmp1, Col1a1, 
Bglap, Mmp9, c-Myc, Alpl or 18S rRNA primers and probes. Reverse transcription was 
performed at 50 ̊C for 10 min followed by 40 cycles of amplification at an annealing 
temperature of 60 ̊C. Reactions for each sample were performed in triplicate. All samples 
were normalized to 18S rRNA, and time zero or vehicle- treated controls using the delta-
delta cycle threshold (DDCt) method.  
5 Data Analysis and Statistical Analyses 
Data are shown as means ± standard error of the mean (S.E.M) for the number (n) of 
experiments indicated, each performed in triplicate. Differences among three or more 
groups were evaluated by two-way analysis of variance (ANOVA) followed by a 
Bonferroni post hoc multiple comparisons test. Differences were accepted as statistically 
significant at p < 0.05. Data analysis was performed using GraphPad Prism 6.0 
(GraphPad Software, San Diego, CA). 
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MC3T3-E1 cells were plated at a density of 1.5x104 cells/cm2 in Falcon 6-well plates in 
culture medium (day 0). After 2 days, cells were placed in serum-free medium and 
incubated overnight with dexamethasone (100 nM) or vehicle (ethanol). On the day of the 
experiment (day 3), cells were incubated with BzATP (300 M) or vehicle (DCFB) at 
time 0 hours. Total RNA was then isolated using Trizol at 0, 0.5, 1, 3 and 6 hours.   
Plate cells 
Vehicle or  
BzATP 
Day 0 Day 1 Day 2 Day 3 
Pretreatment with  
Vehicle or Dexamethasone 
 
Figure 5. Timeline of the experiments 
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RESULTS 
1 BzATP stimulation of Ptgs2 (COX2) was inhibited by dexamethasone 
Ptgs2 is the gene that encodes prostaglandin-endoperoxide synthase 2 also known as 
cyclooxygenase 2 (COX2), a critical enzyme for the synthesis of prostaglandin E2 
(PGE2). Recent studies suggest that a number of effects of P2X7 receptor activation 
during osteoblast mechanotransduction may be mediated via prostaglandins (PGs) such 
as PGE2 (Li et al., 2005).  
Changes in Ptgs2 (COX2) expression were examined in MC3T3-E1 cells following 
treatment with vehicle (DCF Buffer) or BzATP (300 M) in the presence or absence of 
dexamethasone (100 nM). As previously shown by our lab (Grol et al., 2013), BzATP 
induced significant stimulation of Ptgs2 expression (120 ± 46 fold difference) as 
compared to the vehicle-treated cells. Ptgs2 expression reached the peak at 1 h and 
returned to basal levels by 6 h. Statistically significant differences were present between 
vehicle treated cells vs BzATP treatment at 1 h and 3 h (p < 0.001 for both time points) 
whereas dexamethasone alone had no effect on Ptgs2 expression (Figure 6). 
Dexamethasone, however, significantly reduced BzATP induced Ptgs2 expression at 1h 
and 3 h (P < 0.001 for both time points) (Figure 6). 
2 BzATP stimulation of Dmp1 was completely inhibited by dexamethasone 
Dmp1 encodes dentin matrix acidic phosphoprotein 1, which is found in the extracellular 
matrix of bone, dentin and cementum as well as in other non-mineralized tissues (George 
et al., 1993; MacDougall et al., 1998). Dmp1 has been shown to be critical for the 
mineralization of bone and dentin (Feng et al., 2006). Bone cells such as osteocytes, 
osteoblasts and hypertrophic chondrocytes express Dmp1 (Feng et al., 2003; Toyosawa et 
al., 2012).  
We report, for the first time, that BzATP stimulates Dmp1 expression, which peaked at 3 
h post BzATP treatment with a maximum fold difference of 8.4 ± 2.9. Further, this was 
statistically significant at 1 h and 3 h (p < 0.01; p < 0.001, respectively). Dexamethasone 
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completely abolished the BzATP-induced Dmp1 expression (Figure 7; p < 0.01 for 1 h, p 
< 0.001 for 3 h).  
3 BzATP dramatically stimulated c-Fos with no inhibition by dexamethasone, 
indicating specificity  
c-Fos is an immediate early gene, whose activation can be linked to different signaling 
cascades responsible for cell proliferation, differentiation and survival (Dixon and Sims, 
2000). c-Fos plays a crucial role in regulating proliferation and differentiation of bone 
and cartilage cells (Hipskind and Bilbe, 1998). Fos proteins are highly expressed in 
osteoblast precursors, but their levels decline following the initial proliferation stage 
(McCabe et al., 1995). 
We confirmed a dramatic increase in c-Fos expression at an early time point (30 min) 
with BzATP stimulation of P2X7 (Figure 8; p < 0.001 for 0.5 h and p < 0.001 for 1 h). 
However, in contrast to the findings for Ptgs2 and Dmp1, dexamethasone did not inhibit 
this stimulatory effect indicating specificity of dexamethasone action on the expression of 
particular genes (Figure 8).    
4 BzATP and dexamethasone did not affect Col1a1 expression 
We also looked at Col1a1, which encodes collagen type 1 alpha 1 found in connective 
tissues such as bone, tendon and skin. Throughout the 6-hour time course, there were no 
significant effects of BzATP or dexamethasone on Col1a1 expression (Figure 9). The 
same was found for the following genes: Bglap (encoding osteocalcin), Alpl, c-Myc, and 
Mmp9. This does not rule out the possibility of late induction of these genes following 
P2X7 activation since, in the present study, the time course was limited to 6 hours.  
NB: Please refer to Appendix A for data presented as relative gene expression without 
normalization as percentage of the maximum value.  
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Figure 6: Dexamethasone suppresses P2X7-induced expression of Ptgs2 
MC3T3-E1 cells were pretreated with vehicle or dexamethasone (100 nM) overnight and 
then treated with vehicle or BzATP (300 μM) at time 0. Total RNA was isolated at the 
indicated times. RT-PCR was performed to assess expression levels of Ptgs2. Data were 
normalized to levels of 18S ribosomal RNA, and relative to values for vehicle-treated 
cultures at time 0. Data are shown as percentages of the maximum value in each 
individual experiment and are presented as means ± S.E.M. (n = 3 independent 
experiments, each performed in triplicate). The mean maximum value (100%) for these 3 
experiments was 120 ± 46 fold increase relative to vehicle-treated cultures at time 0. 
Differences were evaluated by two-way analysis of variance followed by a Bonferroni 
multiple comparisons test.  indicates significant difference from vehicle/vehicle at each 
time point;  indicates significant effect of dexamethasone pretreatment (p < 0.05). The 
following points were also significantly different than vehicle/vehicle at time 0 – 
BzATP/vehicle at 1h and 3 hrs; BzATP/dexamethasone at 1h. 
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Figure 7: BzATP stimulation of Dmp1 is completely inhibited by dexamethasone 
MC3T3-E1 cells were pretreated with vehicle or dexamethasone (100 nM) overnight and 
then treated with vehicle or BzATP (300 μM) at time 0. Total RNA was isolated at the 
indicated times. RT-PCR was performed to assess expression levels of Dmp1. Data were 
normalized to levels of 18S ribosomal RNA, and relative to values for vehicle-treated 
cultures at time 0. Data are shown as percentages of the maximum value in each 
individual experiment and are presented as means ± S.E.M. (n = 3 independent 
experiments, each performed in triplicate). The mean maximum value (100%) for these 3 
experiments was 8.4 ± 2.9 fold increase relative to vehicle-treated cultures at time 0. 
Statistical analysis was performed as mentioned in methods.  indicates significant 
differences between BzATP treatment and vehicle at each time point;  indicates 
significant differences between BzATP treatment vs. BzATP + Dexamethasone 
pretreatment. (p < 0.05). The following points were also significantly different than 
vehicle/vehicle at time 0 – BzATP/vehicle at 1h and 3 hrs. 
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Figure 8: BzATP stimulates c-Fos expression with no inhibition by dexamethasone  
MC3T3-E1 cells were pretreated with vehicle or dexamethasone (100 nM) overnight and 
then treated with vehicle or BzATP (300 μM) at time 0. Total RNA was isolated at the 
indicated times. RT-PCR was performed to assess expression levels of c-Fos. Data were 
normalized to levels of 18S ribosomal RNA, and relative to values for vehicle-treated 
cultures at time 0. Data are shown as percentages of the maximum value in each 
individual experiment and are presented as means ± S.E.M. (n = 3 independent 
experiments, each performed in triplicate). The mean maximum value (100%) for these 3 
experiments was 279 ± 48 fold increase relative to vehicle-treated cultures at time 0. 
Statistical analysis was performed as mentioned in methods.  indicates significant 
differences from vehicle at each time point; No significant differences between BzATP 
treatment vs. BzATP + dexamethasone pretreatment was found. (p < 0.05). The 
following points were also significantly different than vehicle/vehicle at time 0 – 
BzATP/vehicle at 1h and 3 hrs; BzATP/dexamethasone at 1h and 3 hrs. 
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Figure 9: BzATP and dexamethasone do not affect Col1a1 expression up to 6 hours 
MC3T3-E1 cells were pretreated with vehicle or dexamethasone (100 nM) overnight and 
then treated with vehicle or BzATP (300 μM) at time 0. Total RNA was isolated at the 
indicated times. RT-PCR was performed to assess expression levels of Col1a1. Data were 
normalized to levels of 18S ribosomal RNA, and relative to values for vehicle-treated 
cultures at time 0. Data are shown relative gene expression and are presented as means ± 
S.E.M. (n = 3 independent experiments, each performed in triplicate). Statistical analysis 
was performed as mentioned in methods. No statistically significant differences were 
found between the treatment groups. 
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DISCUSSION 
The P2X7 receptor plays a role in the regulation of osteogenesis and is required for a 
proper skeletal response in mechanical loading. This has important implications in 
orthodontics, as OTM is dependent on mechanotransduction within the alveolar bone.  
The exact role P2X7 plays in osteoblast activation and function and hence osteogenesis 
remains poorly understood. Currently, there is contradicting evidence for the effects of 
P2X7 activation on osteoblast differentiation and bone formation in vitro. While Orriss et 
al. showed inhibition of bone formation with P2X7 activation in rat calvarial osteoblasts 
(Orriss et al., 2012), a previous study by our lab showed an opposite effect of increased 
osteoblast differentiation and bone formation following P2X7 activation in the cell-line 
derived from the same animal model (Panupinthu et al., 2008). 
Orriss et al. attribute their findings to a P2 receptor-dependent and/or receptor 
independent mechanism via hydrolysis of extracellular nucleotides to pyrophosphate, a 
known inhibitor of mineralization (Orriss et al., 2012). In a follow up study, they further 
strengthen their argument by showing that the negative effect of ATP on bone formation 
was reversed with apyrase treatment (which breaks down ATP) (Orriss et al., 2013).  This 
suggests that nucleotide signaling via purinergic receptors may potentially induce an anti-
osteogenic mechanism (Orriss et al., 2013). 
Results from our lab provide evidence of a possible coupling of P2X7 activation with 
production of potent lipid mediators, which may have an osteogenic effect. Panupinthu et 
al. show that P2X7 activation of osteoblast function may involve phospholipase D and 
phospholipase A2 stimulation leading to the production of LPA and PGE2, which 
contribute to enhanced osteogenesis (Panupinthu et al., 2007; Panupinthu et al., 2008). 
LPA signaling involves Rho-associated kinase, which has established roles in driving 
non-committed cells towards osteoblast lineage (McBeath et al., 2004). In addition, Grol 
et al. showed that Ca2+ influx following P2X7 activation causes a sustained increase in 
metabolic acid efflux (measurement of osteoblast cellular activity) dependent on glucose 
and phosphatidylinositol 3-kinase activity (Grol et al., 2012). Furthermore, the ATP 
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induced Ca2+ signalling in osteoblasts is dose and duration dependent and is transduced to 
distinct cellular signals (Grol et al., 2013). Low concentrations of ATP (1 nM to 100 M) 
act through P2Y receptors to elicit transient Ca2+-NFAT (nuclear factor of activated T-
cells) signaling whereas high ATP concentrations (300 M to 10 mM) act through P2X7 
to induce a more sustained Ca2+-NFAT signaling ultimately stimulating expression of 
Ptgs2 (COX2) (Grol et al., 2013). This up-regulation of Ptgs2(COX2) may translate to an 
increased production of PGE2. 
Further evidence supporting positive role of P2X7 in osteoblasts include the observations 
of reduced alkaline phosphatase activity in osteoblasts isolated from P2X7 KO rats 
(Panupinthu et al., 2008), decreased periosteal bone formation in long bones of P2X7 KO 
mice (Ke et al., 2003), and their reduced osteogenesis in response to mechanical loading 
(Li et al., 2005). In addition, several polymorphisms in the P2X7 leading to reduced 
function of the P2X7 are associated with increased risk of osteoporosis in humans 
(Gartland et al., 2012; Jorgensen et al., 2012; Ohlendorff et al., 2007). 
The discrepancy observed between the findings of Orriss et al. and our lab may be 
attributed to the differences in the experimental set up. Upon review of the culture 
conditions, we noted several differences: a) dexamethasone was added to the culture 
media used by Orriss et al. due to that fact that glucocorticoids have been shown to be 
osteogenic in vitro (Bellows et al., 1994) b) duration of culture period, and c) the age of 
the animals at the time cells were isolated. Given the pleiotropic nature of glucocorticoid 
action in bone, we suspect that dexamethasone may be the reason behind the 
contradicting observations.  
In this study, we examined the changes in gene expression triggered by BzATP activation 
of endogenous P2X7 receptors in osteoblasts. Furthermore, we examined the effect 
dexamethasone has on BzATP induced gene expression in an effort to clarify the 
mechanism of action dexamethasone has on osteoblast differentiation and function. 
Ptgs2 is the gene that encodes prostaglandin-endoperoxide synthase 2 also known as 
cyclooxygenase 2 (COX2), a critical enzyme for the synthesis of prostaglandin E2 
(PGE2). Recent studies suggest that a number of effects of P2X7 receptor activation 
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during osteoblast mechanotransduction may be mediated via prostaglandins (PGs) such 
as PGE2 (Li et al., 2005).  
Prostaglandins are important mediators of mechanical stress (Blackwell et al., 2010). 
Other stimulants such as growth factors (Platelet-derived growth factors [PDGF]), 
hormones (parathyroid hormone [PTH]), and interleukins and other cytokines also induce 
PGE2 production and affect bone remodeling and tooth movement (Blackwell et al., 
2010). Clinical and animal studies have demonstrated the role of PGs in modulating bone 
remodeling by stimulating bone resorption and bone formation. PGs increase osteoclast 
number as well as their capacity to form a ruffled border resulting in subsequent increase 
in bone resorption (Klein, 1970). In orthodontics, orthodontic force application induces 
the synthesis of PGs, which in turn stimulate osteoclastic bone resorption (Davidovitch et 
al., 1988; Yamasaki et al., 1984). A local injection of PGs into the paradental tissues of 
rodents resulted in an increase in osteoclast numbers (Yamasaki et al., 1984). Moreover, 
a reduced rate of tooth movement was observed after the administration of indomethacin, 
an anti-inflammatory agent which inhibits PG synthesis by blocking COX1 and COX2 
(Chumbley and Tuncay, 1986). The exact mechanistic role of PGs in bone resorption is 
not clear but it is thought to stimulate cells to produce cyclic adenosine monophosphate, 
which is an important chemical messenger for bone resorption (Klein, 1970; Raisz and 
Koolemans-Beynen, 1974). In osteoblastic cells, PGE2 stimulates their differentiation and 
eventual new bone formation, coupling bone resorption in vitro (Blackwell et al., 2010). 
Recent work from our lab has shown that Ca2+-NFAT signaling pathway stimulates 
expression of Ptgs2 (COX2) downstream of the P2X7 receptor in osteoblasts within 3 
hours of ATP treatment (Grol et al., 2013) further suggesting that PGE2 produced by the 
activation of P2X7 may act as an autocrine factor for osteoblast activation. 
Given the important role of COX2 and PGE2 in osteoblast differentiation and responses 
to mechanical stimuli (Blackwell et al., 2010), we examined changes in Ptgs2 expression 
following ATP activation of P2X7. We confirm that BzATP stimulation of P2X7 leads to 
a significant increase in Ptgs2 expression at similar time points as observed in our 
previous study (Grol et al., 2013). Furthermore, we show, for the first time, that BzATP 
induced Ptgs2 expression is inhibited markedly by dexamethasone (Figure 6). This 
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inhibitory action of dexamethasone on Ptgs2 gene expression may help explain the 
current controversy surrounding the exact role of P2X7 activation in osteoblasts. 
Moreover, this may also help deduce the mechanism of action of glucocorticoids in bone 
cells at a transcriptional level. 
Interestingly, we show that dexamethasone’s inhibitory effect on Ptgs2 was incomplete 
as there was evidence of some Ptgs2 expression. This may be explained by multiple 
factors. First, the extent of inhibition may be dependent on the concentration of 
dexamethasone in a dose-dependent manner. It is possible that we would see greater 
inhibition with a dose larger than 100 nM as used in this study. Secondly, we cannot rule 
out the involvement of other signaling pathways or other P2 receptors whose signaling 
pathways may not be sensitive to dexamethasone.  
Dmp1 gene encodes dentin matrix acidic phosphoprotein 1, an extracellular matrix 
protein that belongs to the small integrin-binding ligand, N-linked glycoprotein 
(SIBLING) family of proteins (Staines et al., 2012). Dentin matrix acidic phosphoprotein 
1 is found in the extracellular matrix of bone, dentin and cementum as well as in other 
non-mineralized tissues (George et al., 1993; MacDougall et al., 1998). Dmp1 is critical 
for the mineralization of bone and dentin, as mutations in the gene are known to cause 
autosomal recessive hypophosphatemia, which can manifest as rickets and osteomalacia 
(Feng et al., 2006). In bone, Dmp1 is expressed in osteocytes, osteoblasts and 
hypertrophic chondrocytes (Feng et al., 2003; Toyosawa et al., 2012). 
In this study, a significant stimulation of Dmp1 expression with BzATP is also observed, 
although not to the same fold difference as seen with Ptgs2 (120 ± 46 [Ptgs2] vs 8.4 ± 2.9 
[Dmp1]), (Figure 7). Dmp1 expression peaks at a later time point than Ptgs2 which may 
be due to the fact that the genes required for the matrix proteins are activated downstream 
of Ptgs2. Interestingly, there was a complete inhibition of Dmp1 stimulation by 
dexamethasone. In contrast to Ptgs2, the signaling pathway that leads to Dmp1 
expression may be highly dependent on P2X7 and selectively inhibited by 
dexamethasone. 
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As mentioned briefly in the introduction, extracellular stimuli regulate gene expression 
via the activation of intracellular signaling systems that transduce the signal from 
membrane-bound receptors to transcription factors. This results in the rapid, transient 
induction of genes known as “immediate early gene” whose products mediate the 
appropriate cellular response. c-Fos is an example of an immediate early gene, whose 
activation can be linked to different signaling cascades targeting distinct promoter 
elements through the phosphorylation of transcription factors (Dixon and Sims, 2000). 
Fos proteins are highly expressed in osteoblast precursors, but their levels decline 
following the initial proliferation stage (McCabe et al., 1995). 
c-Fos encodes a transcription factor which, as part of an activator protein 1 (AP-1) 
complex, plays a crucial role in regulating proliferation and differentiation of bone and 
cartilage cells (Hipskind and Bilbe, 1998). c-Fos induction plays an important role in 
vitro in driving immortalized fibroblasts to enter the cell cycle and plays an important 
role in vivo in the skeletal system (Bowler et al., 1999). Mice overexpressing c-Fos 
develop osteosarcomas and chondrosarcomas, whereas mice lacking c-Fos fail to develop 
osteoclasts and thus develop osteopetrosis in which the bone remodeling process 
becomes shifted towards bone accumulation (David et al., 2005; Johnson et al., 1992; 
Wang et al., 1992). These findings implicate that c-Fos plays a key role in the regulation 
of skeletal cells. Accordingly, a number of proteins found in differentiating bone cells 
have regulatory AP-1 sites in their promoters, and a variety of extracellular factors 
involved in osteogenesis activate c-Fos transcription in cultured bone cells in vitro 
(Evans, 1996; Hipskind and Bilbe, 1998).  
It has previously been shown by our lab that extracellular ATP rapidly increases c-Fos 
mRNA in UMR-106 osteoblastic cells at levels as low as 10 M via P2 receptors (Dixon 
and Sims, 2000). It has also been shown that nucleotides potentiate the induction of c-Fos 
expression by parathyroid hormone in the human osteoblast-like cell line SaOS-2 and in 
primary human bone derived cells (Bowler et al., 1999). 
In this study, we confirm the findings reported thus far and show that BzATP activation 
of P2X7 receptors lead to a rapid and dramatic induction of c-Fos expression. Within 30 
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minutes of BzATP treatment, we observed a 279 ± 48 fold increase in c-Fos expression 
as compared to the vehicle treated cells. In contrast to the previous 2 genes presented, 
dexamethasone does not significantly affect this stimulatory effect (Figure 8). This 
further corroborates with our hypothesis that BzATP stimulation of P2X7 leads to an up-
regulation of osteogenic genes as c-Fos 1) promotes proliferation of osteoblasts and 2) as 
a transcription factor, it may trigger downstream signaling events which may eventually 
lead to up-regulation of various osteogenic genes. The finding that dexamethasone does 
not have an inhibitory effect on c-Fos expression may be attributed to the specificity of 
dexamethasone action.  It is possible that dexamethasone only affects a specific set of 
genes directly involved in osteoblast differentiation. 
Additionally, we examined other transcription factors as well as genes that encode 
various matrix proteins expressed during osteoblast differentiation. As mentioned in the 
introduction, a series of transcriptional events control the commitment of mesenchymal 
stem cells to a mature osteoblast. To summarize, RUNX2 is a key transcription factor 
controlling osteoblast differentiation. Osterix (OSX) acts downstream of RUNX2 and is 
specific for early and late stages of osteoblast differentiation (Koga et al., 2005; 
Nakashima et al., 2002; Nishio et al., 2006). The combined expression of RUNX2 and 
OSX initiates development of the committed preosteoblast which is characterized by 
expression of COL1 and BSP. Subsequent induction of activating transcription factor 4 
(ATF-4) together with OSX and various Wnt/-catenin signaling components leads to 
development of the mature osteoblast which express COL1, alkaline phosphatase (ALP) 
and osteocalcin (OCN) (Grol et al., 2009).  
Type 1 collagen (COL1) is a major organic constituent of the extracellular matrix in 
bone. Its main function is to provide scaffolding for the nucleation of hydroxyapatite 
crystals during calcification. Non-collagenous proteins aid in the organization of the 
collagen matrix and regulate the formation and growth of hydroxyapatite crystals. 
Osteocalcin is the most abundant non-collagenous bone matrix protein (Wolf, 1996). It is 
a small carboxyglutamate protein expressed preferentially by osteoblasts and can bind 
calcium ions (Boivin et al., 1990). Alkaline phosphatase hydrolyzes ester bonds in 
organic phosphate compounds under alkaline conditions and plays an important role in 
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bone calcification (Anderson, 1989). Mmp9 encodes for matrix metalloproteinase 9 
which is an enzyme responsible for degrading extracellular matrix in physiological and 
pathological processes. It has been shown that RUNX2 mediates transactivation of the 
Mmp9 promoter site in MC3T3-E1 cells (Pratap et al., 2005). 
In this study, we show for the first time that neither BzATP nor dexamethasone affect the 
expression of Col1a1, Bglap (encoding osteocalcin), Alpl and Mmp9 up to 6 hours 
(Figure 9). This does not rule out the possibility of late induction of these genes following 
P2X7 activation since the time course was limited to 6 hours in the present study. Genes 
involved in matrix formation and maturation may be induced days following P2X7 
activation. Indeed, a recent study by Kariya et al. show that tension-force induced P2X7 
activation resulted in the up-regulation of RUNX2 and OSX in earlier time points (3 h 
and 6 h respectively), while COL1 and BSP peaked at day 3 and day 7 respectively 
(Kariya et al., 2015). Moreover, the expression of genes encoding downstream matrix 
proteins expressed by mature osteoblasts, OPN, OCN and ALP, peaked on day 14 of 
culture (Kariya et al., 2015). It would be informative to extend the time course and 
observe the changes in the expression of matrix genes upon P2X7 activation. 
We also looked at c-Myc, another regulator gene that codes for a transcription factor. The 
protein encoded by the c-Myc gene is a multifunctional nuclear phosphoprotein that plays 
a role in cell cycle progression, growth, differentiation and apoptosis. Similar to c-Fos, c-
Myc is also a proto-oncogene as its expression is often up-regulated in various forms of 
cancer. c-Myc expression is activated upon various signaling pathways such as Wnt and 
EGF (Ran et al., 1986; Zhang et al., 2012). It is also shown to be dependent on BMP 
induced signaling as it was shown to increase in BMP induced osteogenesis (Piek et al., 
2010; Sakano et al., 1997). Here we showed that c-Myc expression was not affected by 
either BzATP or dexamethasone up to 6 hours. This could be due to the possibility that c-
Myc expression may be dependent on a signaling pathway distinct from those activated 
upon P2X7 activation. 
 
 
42 
 
There are a few limitations of this study that should be noted.  
a) Firstly, we used a mouse osteoblast precursor cell line. As there are inherent 
species-specific differences between a mouse and human osteoblastic cell line, 
this may translate to differences in molecular interactions in bone remodeling as 
well.  
b) Secondly, BzATP may not specifically activate P2X7 as it is known to also 
stimulate other P2X receptors such as P2X1 with high affinity. Some of the 
effects seen in the study may be a result of a compounded effect of P2X receptors. 
c) Thirdly, it would have been helpful to have a control (time 0 hours) sample of 
cells treated overnight with dexamethasone. During the optimization process, we 
changed conditions from simultaneous treatment with dexamethasone and BzATP 
to overnight pretreatment of dexamethasone. However, due to an oversight, time 0 
samples for dexamethasone treatment groups were not collected. Thus, it is 
possible that dexamethasone alone affects the expression of certain genes 
irrespective of BzATP action. In such cases, we do not have the time 0 control 
with which to compare changes in gene expression. However, this does not affect 
our conclusions regarding the actions of dexamethasone on responses to BzATP. 
In the future, a time 0 control for dexamethasone-treated cells should be included.   
d) Lastly, findings in the calvaria bone cells may not be extended to the jaw bones as 
bone characteristics may be site-specific (Judex et al., 2004). The differences 
between the different bone types may translate to differences in bone 
mechanotransduction. Viecilli et al studied the dentoalveolar morphology in WT 
and P2X7 KO mice and found no statistically significant differences between the 
two mouse types (Viecilli et al., 2009a). They conclude that P2X7 does not seem 
to have a major effect on alveolar bone or tooth morphology and that its effects 
may be site-specific to long bones. However, in a separate study published in the 
same year by the same group, the role of the P2X7 in orthodontic mechanical 
loading was investigated via P2X7 KO mouse model (Viecilli et al., 2009b). They 
show that hyalinization and root and bone resorption were different in the 2 types 
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of mice (increased in the KO mouse) and conclude that P2X7 plays a significant 
role in orthodontic mechanotransduction (Viecilli et al., 2009b). Nevertheless, 
there is a possibility that our findings may not be extrapolated to alveolar bones.  
 
In conclusion, we show for the first time that dexamethasone inhibits osteogenic 
activities in bone cells in response to mechanical stimulus. As we hypothesized, the 
expression of anabolic genes such as Ptgs2 and Dmp1 are stimulated by BzATP 
activation of the P2X7 receptor. However, this is inhibited by dexamethasone confirming 
that dexamethasone may indeed have an inhibitory role in osteoblast differentiation and 
activation and eventual bone formation (Figure 10). In contrast to Ptgs2 and Dmp1, the 
expression of c-Fos is stimulated with BzATP but not significantly affected by 
dexamethasone. This may indicate that dexamethasone specifically inhibits the 
expression of particular genes. We examined various other genes involved in osteoblast 
activation and bone formation and did not find a significant effect of BzATP stimulation 
with these genes up to 6 hours. An extended time course performed in primary osteoblast 
differentiation study is necessary to see if indeed these genes are regulated via P2X7 
activation at later time points and whether dexamethasone has an effect. 
It is also possible that while a transient activation of P2X7 is osteogenic, sustained 
stimulation could inhibit osteoblast function and activity (Agrawal and Gartland, 2015). 
It has been shown that, while short term application of BzATP induces reversible 
membrane blebbing without the activation of the key apoptotic mediator caspase-3 in 
murine osteoblastic cells (Li et al., 2005; Panupinthu et al., 2007), longer agonist stimulus 
can cause extensive membrane blebbing and ultimately lead to apoptosis (Gartland et al., 
2001). 
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Suggestions for Future Studies 
a) An important follow up to this study would be to repeat the study with P2X7 
specific antagonists. This will strengthen the argument that the effects seen here 
were due to activation of P2X7 rather than other P2 receptors.  
b) A differentiation study done in a primary osteoblast culture looking at a longer 
timeline post ATP treatment should clarify whether the expression level of the 
genes involved in matrix mineralization is affected. 
c) Future work should also assess the amount of bone formation in primary rat or 
mouse osteoblasts with BzATP treatment in the presence of absence of 
dexamethasone. We hypothesize that an increased bone formation will be seen 
with BzATP treatment and that dexamethasone will reverse these effects.  
d) It would also be informative to measure the level of PGE2 in the cell supernatant 
with an enzyme-linked immunosorbent assay (ELISA) to confirm the downstream 
effects of BzATP induced COX2 expression.  
e) Repeating this study with PGE2 and LPA receptor antagonist will help further 
clarify the downstream signalling events following P2X7 activation and help 
dissect the autocrine/paracrine mechanism of osteoblast activation. 
f) It will be of interest to perform a dose dependent study with ATP as well as 
dexamethasone. It is possible that downstream signaling events following ATP-
mediated P2X7 activation are dose and duration dependent (Grol et al., 2013). 
Dexamethasone action may also vary depending on the dosage and the duration of 
pre-treatment. We can vary the dose and the duration of dexamethasone pre-
treatment and study the effect on dexamethasone-induced inhibition of osteogenic 
gene expression and bone formation. 
g) Eventually, it will be helpful to reproduce this study in an animal model such as 
mouse. We can treat P2X7 KO and wild type mice with or without 
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dexamethasone treatment and observe the differences in bone remodeling upon 
mechanical loading by studying the response in bone.  
Last section of this thesis will briefly discuss the clinical relevance of the current findings 
in orthodontics and bone physiology. 
Relevance of the Study in Orthodontic Tooth Movement 
There are few studies directly addressing the biological mechanisms underlying 
mechanotransduction in orthodontics. In this study, we set out to elucidate molecular 
interactions during bone remodeling occurring in orthodontic tooth movement in order to 
better understand the relationship between genes and transcription factors implicated in 
bone remodeling. Expanding our basic science knowledge of the underlying mechanisms 
of OTM will help improve orthodontic mechanotherapy to be more biologic and efficient. 
Any interference responsible for inhibiting or delaying the sequence of events following 
mechanical stimulation leading to bone remodeling can have a negative effect on OTM. 
Here we show that dexamethasone may inhibit osteoblast maturation and bone formation 
via its inhibitory action on osteogenic gene expression. This finding may help explain 
why patients who have been on long-term corticosteroid therapy may react differently to 
orthodontic forces (Kalia et al., 2004). Initially, reduced bone formation may translate to 
an increased rate of tooth movement during active orthodontic treatment but decrease 
long-term stability during the retention phase. Hence, orthodontic patients on 
corticosteroid therapy may be more prone to post-treatment relapse and it may be 
necessary to implement a more stringent retention measures.  
Relevance of the Study in Glucocorticoid-Induced Osteoporosis 
Glucocorticoid-induced osteoporosis is a serious side effect of glucocorticoid therapy 
which can lead to fractures in 30 - 50% of patients (Fraser and Adachi, 2009). The 
mechanisms we have shown in this study may contribute to glucocorticoid-induced 
osteoporosis as we show that up-regulation of certain osteogenic genes on mechanical 
loading were inhibited by dexamethasone. 
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Furthermore, we suspect that patients suffering from glucocorticoid-induced osteoporosis 
may not respond favourably to exercise. Such patients may not react to mechanical 
loading the same way a normal healthy individual would. As observed in the study by 
Orriss et al, P2X7 activation in the presence of dexamethasone may trigger a distinct 
signaling pathway leading to inhibition of bone formation causing an imbalance in bone 
remodeling (Orriss et al., 2012; Orriss et al., 2013). Therefore, dexamethasone may 
possibly worsen the condition by inhibiting osteogenesis and promoting bone resorption.   
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SUMMARY AND CONCLUSIONS 
 
• We confirmed that the P2X7 agonist BzATP stimulates expression of Ptgs2 in 
osteoblastic cells. 
• We show, for the first time, that BzATP stimulates expression of Dmp1. 
• We also show, for the first time, that BzATP stimulation of Ptgs2 (Cox2) and 
Dmp1 expression is inhibited by dexamethasone. 
• BzATP dramatically stimulates c-Fos expression at early time points with no 
inhibition by dexamethasone. This indicates that the inhibitory effects of 
dexamethasone are specific for the expression of particular genes. 
• In contrast, neither BzATP nor dexamethasone significantly affects the expression 
levels of Col1a1, c-Myc, Bglap, Alpl or Mmp9. 
• Consistent with our hypothesis, dexamethasone inhibits the ability of BzATP to 
stimulate the expression of two anabolic genes (Ptgs2 and Dmp1) in osteoblastic 
cells). 
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Figure 10. Summary of the findings 
We show for the first time that dexamethasone inhibits osteogenic activities in bone cells 
in response to mechanical stimulus. We confirmed that the P2X7 agonist BzATP 
stimulates expression of Ptgs2 and Dmp1 in osteoblastic cells. However, this is inhibited 
by dexamethasone confirming that dexamethasone may indeed have an inhibitory role in 
osteoblast differentiation and function, and eventual bone formation. In contrast to Ptgs2 
and Dmp1, the expression of c-Fos is stimulated with BzATP but not significantly 
affected by dexamethasone. This may indicate that dexamethasone specifically inhibits 
the expression of particular genes. 
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APPENDICES 
Appendix A: Results presented without the normalization as percentage of 
maximum gene expression.   
Data are shown as relative gene expression of respective genes.  
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Appendix B: Permission to use Figure 4.  
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